Trending Now

Nivesh.live

Invest Wisely, Grow Steadily

Menu
Search
Headline
10 reasons why gold is a good buy in 2025 – CNBC TV18
10 reasons why gold is a good buy in 2025 – CNBC TV18
Tata Motors shares up 5% but tariff troubles continue to linger – CNBC TV18
Tata Motors shares up 5% but tariff troubles continue to linger – CNBC TV18
Muthoot Finance shares fall over 8% in reaction to draft RBI norms, Kotak downgrade – CNBC TV18
Muthoot Finance shares fall over 8% in reaction to draft RBI norms, Kotak downgrade – CNBC TV18
National Pet Day 2025: A look at pet insurance coverage in India and what’s included – CNBC TV18
National Pet Day 2025: A look at pet insurance coverage in India and what’s included – CNBC TV18
Bharti Hexacom shares in focus after deal to sell 3,400 towers to Indus Towers halted – CNBC TV18
Bharti Hexacom shares in focus after deal to sell 3,400 towers to Indus Towers halted – CNBC TV18
Samvardhana Motherson aims for €50 million in cost savings with latest measures – CNBC TV18
Samvardhana Motherson aims for €50 million in cost savings with latest measures – CNBC TV18
Asian shares sink, with Japan’s Nikkei down 5.6% as China-US trade war escalates – CNBC TV18
Asian shares sink, with Japan’s Nikkei down 5.6% as China-US trade war escalates – CNBC TV18
GIFT Nifty surges nearly 500 points indicating a potential gap-up despite US sell-off – CNBC TV18
GIFT Nifty surges nearly 500 points indicating a potential gap-up despite US sell-off – CNBC TV18
Sensex Today | Stock Market LIVE Updates: Sensex, Nifty 50 likely to make a gap down start on Wednesday
Sensex Today | Stock Market LIVE Updates: Sensex, Nifty 50 likely to make a gap down start on Wednesday

Tag: Glenmark Therapeutics Inc USA

Markets
Sarvesh Gautam

Glenmark Pharmaceuticals secures US FDA approval for Olopatadine ophthalmic solution – CNBC TV18

[ad_1] Glenmark Pharmaceuticals Ltd on Thursday (March 20) said its arms Pharmaceuticals Inc., USA, has received final approval from the US Food & Drug Administration (USFDA) for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC). The product has been determined to be bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), developed by Alcon […]

Back To Top
Translate »